Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10201/56215

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorDitsch, Nina-
dc.contributor.authorToth, Bettina-
dc.contributor.authorHimsl, Isabelle-
dc.contributor.authorLenhard, Miriam-
dc.contributor.authorOchsenkühn, Robert-
dc.contributor.authorFriese, Klaus-
dc.contributor.authorMayr, Doris-
dc.contributor.authorJeschke, Udo-
dc.date.accessioned2018-02-19T10:16:16Z-
dc.date.available2018-02-19T10:16:16Z-
dc.date.issued2013-
dc.identifier.citationHistology and Histopathology, vol. 28, nº 2, (2013)es
dc.identifier.issn1699-5848-
dc.identifier.issn0213-3911-
dc.identifier.urihttp://hdl.handle.net/10201/56215-
dc.description.abstractThere is evidence that breast cancer patients suffer from thyroid disorders. However, the relation between thyroid receptor (TR) expression and breast cancer remains unknown so far. Therefore, the aim of this study was an immunohistochemical analysis of TR expression in breast cancer patients. Materials and methods: The expression of the combined antibody TRalpha1 and 2 and TRalpha1 or 2 alone as well as the expression of combined TRbeta1 and 2 and TRbeta1 or 2 alone was investigated with specific monoclonal or polyclonal antibodies in 82 patients. All patients presented with a first diagnosis of sporadic breast cancer. The ABC method was used for staining and staining intensities were analyzed using the IRS score. Results: Both TRalpha and TRbeta were expressed in the nuclei of breast cancer cells. In 24% (28/78) of the slides TRalpha1 and 2 IRS was positive. Immunopositivity for TRalpha1 was found in 55/78 slides, for TRalpha 2 in 54/79 slides (71 and 68%, respectively). The expression of TRbeta1 and 2 showed a positive detection in 33/77 (43%) of the slides, for TRbeta1 it was 43/79 (54%), for TRbeta2 60/76 (79%). Significant correlations of the expression of TRs - especially TRalpha2 - were found with further prognostic histopathological parameters such as tumor size, axillary lymph node involvement, grading and hormone receptor status. Multivariate analysis showed a trend for TRalpha2 as an independent predictor of disease-free and overall survival. Discussion: Our results revealed specific alterations in the expression of TRs - especially of TRalpha2 - in breast cancer patients, suggesting it as a marker with possible prognostic validity.es
dc.formatapplication/pdfes
dc.format.extent11es
dc.languageenges
dc.publisherF. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histologíaes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.subjectBreast canceres
dc.subjectThyroid hormone receptor alphaes
dc.subjectThyroid hormone receptor betaes
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicinaes
dc.titleThyroid hormone receptor (TR)alpha and TRbeta expression in breast canceres
dc.typeinfo:eu-repo/semantics/articlees
Aparece en las colecciones:Vol.28, nº 2 (2013)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Ditsch-28-227-237-2013.pdf8,02 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons